ATE57833T1 - Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung. - Google Patents

Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.

Info

Publication number
ATE57833T1
ATE57833T1 AT84305911T AT84305911T ATE57833T1 AT E57833 T1 ATE57833 T1 AT E57833T1 AT 84305911 T AT84305911 T AT 84305911T AT 84305911 T AT84305911 T AT 84305911T AT E57833 T1 ATE57833 T1 AT E57833T1
Authority
AT
Austria
Prior art keywords
amosulalol hydrochloride
lasting
long
acid
amosulalol
Prior art date
Application number
AT84305911T
Other languages
German (de)
English (en)
Inventor
Takashi Sonobe
Hiroshi Sugiura
Tomoh Itoh
Masayoshi Aruga
Hiroitsu Kawata
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Application granted granted Critical
Publication of ATE57833T1 publication Critical patent/ATE57833T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT84305911T 1983-08-31 1984-08-29 Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung. ATE57833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58160086A JPS6051106A (ja) 1983-08-31 1983-08-31 塩酸アモスラロ−ル持続性製剤
EP84305911A EP0136103B1 (en) 1983-08-31 1984-08-29 Amosulalol hydrochloride long acting formulations

Publications (1)

Publication Number Publication Date
ATE57833T1 true ATE57833T1 (de) 1990-11-15

Family

ID=15707557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84305911T ATE57833T1 (de) 1983-08-31 1984-08-29 Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.

Country Status (7)

Country Link
US (2) US4724148A (cg-RX-API-DMAC7.html)
EP (1) EP0136103B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6051106A (cg-RX-API-DMAC7.html)
KR (1) KR910002670B1 (cg-RX-API-DMAC7.html)
AT (1) ATE57833T1 (cg-RX-API-DMAC7.html)
DE (1) DE3483504D1 (cg-RX-API-DMAC7.html)
ES (1) ES8602406A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
ATE124864T1 (de) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
ATE120089T1 (de) * 1991-05-20 1995-04-15 Marion Laboratories Inc Mehrschichtige zubereitung mit kontrollierter freisetzung.
WO1993024121A1 (fr) * 1992-05-22 1993-12-09 Senju Pharmaceutical Co., Ltd. Medicament pour le glaucome
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
CA2327543A1 (en) * 1998-05-06 1999-11-11 Duke University Method of treating bladder and lower urinary tract syndromes
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
AU1169601A (en) * 1999-11-16 2001-05-30 Ranbaxy Laboratories Limited Taste masked oral compositions
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
CN101854920B (zh) 2007-10-19 2013-05-01 大塚制药株式会社 基质型药物固体制剂
DE102011012517A1 (de) * 2011-02-25 2012-08-30 Renolit Ag Verfahren zum Schutz von Oberflächen vor Bewuchs
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS535728B2 (cg-RX-API-DMAC7.html) * 1974-01-12 1978-03-01
CA1097220A (en) * 1975-10-10 1981-03-10 Aaron L. Weiss Controlled release tablet
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤

Also Published As

Publication number Publication date
JPS6051106A (ja) 1985-03-22
US4724148A (en) 1988-02-09
EP0136103A3 (en) 1986-10-22
KR850001693A (ko) 1985-04-01
ES535545A0 (es) 1985-12-01
EP0136103A2 (en) 1985-04-03
JPH0443049B2 (cg-RX-API-DMAC7.html) 1992-07-15
KR910002670B1 (ko) 1991-05-03
EP0136103B1 (en) 1990-10-31
DE3483504D1 (de) 1990-12-06
ES8602406A1 (es) 1985-12-01
US4765988A (en) 1988-08-23

Similar Documents

Publication Publication Date Title
ATE57833T1 (de) Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.
SK90794A3 (en) Carbamates and plant-protecting agents containing them
ATE41739T1 (de) Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.
DE69419263D1 (de) Herbizide zusammensetzungen in form einer diphenylether- und stickstofflösung und verfahren
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
IT8121022A0 (it) Procedimento e apparecchiatura perl'allineamento di maschere/fette di silicio.
TR199700727T1 (xx) Farnesil transferaz�n�n yeni inhibit�rleri.
IT8519873A0 (it) Procedimento di solubilizzazione di principi attivi e composizioni farmaceutiche cosi' ottenute.
IT1131750B (it) Formulazioni stabili di n-(3,4-diclorofenil)-n'metossi-n'-metilurea (linorun) e 2,6-dinitor-n,n-dipropil-4-trifluoro metilanilina (trifluralin) in emulsione
ES2042556T3 (es) N,n'-diacilhidrazinas n-sustituidas, n'-sustituidas insecticidas.
DK239984A (da) Fremgangsmaade til perkutan indgivning af fysiologisk aktive midler
TR20232A (tr) Cis-9-trikosen ve metomil'den olusan ensektisit bilesim
BG31463A3 (bg) Инсектицидно средство
DE3561153D1 (de) Benzoylurea derivatives
IT1157914B (it) Formulazioni insetticide a base di piretroidi e esteritioffosforici
SE8002642L (sv) Analgetiska och myotonolytiska preparat
ES8706138A1 (es) Procedimiento para la obtencion de nuevas benzoilureas
NZ192771A (en) N-(4-alkenylthio-phenyl)-n'-benzoylureas and insecticidal compositions
ES2053686T3 (es) Nuevos di(met)acrilatos, procedimiento para su fabricacion y su empleo.
DK363383D0 (da) Fungicide midler
IT1152114B (it) Procedimento di alogenazione di n-(0,0'-dialchilfenil) alaninati e omologhi
DE3162447D1 (en) Pesticide agents
SE8304162L (sv) Fungicid beredning
JPS53124267A (en) 1-alkoxyacyl-3-(3,5-dihalogenophenyl)hydantoin derivatives, their preparation and bactericides for agricultural and horticultural uses containing the same as active agent
IT1135788B (it) Perfezionamento alle apparecchiature spandi-erba ed equivalenti applicazioni agrarie,e relative apparecchiature perfezionate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee